305 related articles for article (PubMed ID: 32320239)
1. Dual-Target Inhibitors Based on HDACs: Novel Antitumor Agents for Cancer Therapy.
Liu T; Wan Y; Xiao Y; Xia C; Duan G
J Med Chem; 2020 Sep; 63(17):8977-9002. PubMed ID: 32320239
[TBL] [Abstract][Full Text] [Related]
2. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
3. Identification of type-specific anticancer histone deacetylase inhibitors: road to success.
Noureen N; Rashid H; Kalsoom S
Cancer Chemother Pharmacol; 2010 Sep; 66(4):625-33. PubMed ID: 20401613
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis and anticancer evaluation of acridine hydroxamic acid derivatives as dual Topo and HDAC inhibitors.
Chen J; Li D; Li W; Yin J; Zhang Y; Yuan Z; Gao C; Liu F; Jiang Y
Bioorg Med Chem; 2018 Aug; 26(14):3958-3966. PubMed ID: 29954683
[TBL] [Abstract][Full Text] [Related]
5. Current status in the discovery of dual BET/HDAC inhibitors.
Ren Q; Gao W
Bioorg Med Chem Lett; 2021 Jan; 31():127671. PubMed ID: 33229136
[TBL] [Abstract][Full Text] [Related]
6. Development and therapeutic impact of HDAC6-selective inhibitors.
Dallavalle S; Pisano C; Zunino F
Biochem Pharmacol; 2012 Sep; 84(6):756-65. PubMed ID: 22728920
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting of histone deacetylase and topoisomerase II with novel bifunctional inhibitors.
Guerrant W; Patil V; Canzoneri JC; Oyelere AK
J Med Chem; 2012 Feb; 55(4):1465-77. PubMed ID: 22260166
[TBL] [Abstract][Full Text] [Related]
8. Recent progress in the development of histone deacetylase inhibitors as anti-cancer agents.
Zhang L; Lei J; Shan Y; Yang H; Song M; Ma Y
Mini Rev Med Chem; 2013 Dec; 13(14):1999-2013. PubMed ID: 24160707
[TBL] [Abstract][Full Text] [Related]
9. Structure-activity relationships of HDAC8 inhibitors: Non-hydroxamates as anticancer agents.
Amin SA; Adhikari N; Jha T
Pharmacol Res; 2018 May; 131():128-142. PubMed ID: 29514055
[TBL] [Abstract][Full Text] [Related]
10. Novel Approaches Towards Designing of Isoform-Selective Inhibitors Against Class II Histone Deacetylases: The Acute Requirement for Targetted Anticancer Therapy.
Ganai SA
Curr Top Med Chem; 2016; 16(22):2441-52. PubMed ID: 26873193
[TBL] [Abstract][Full Text] [Related]
11. Natural products as zinc-dependent histone deacetylase inhibitors.
Tan S; Liu ZP
ChemMedChem; 2015 Mar; 10(3):441-50. PubMed ID: 25581683
[TBL] [Abstract][Full Text] [Related]
12. Kinase and Histone Deacetylase Hybrid Inhibitors for Cancer Therapy.
Luan Y; Li J; Bernatchez JA; Li R
J Med Chem; 2019 Apr; 62(7):3171-3183. PubMed ID: 30418766
[TBL] [Abstract][Full Text] [Related]
13. The synergistic effects of DNA-targeted chemotherapeutics and histone deacetylase inhibitors as therapeutic strategies for cancer treatment.
Stiborová M; Eckschlager T; Poljaková J; Hraběta J; Adam V; Kizek R; Frei E
Curr Med Chem; 2012; 19(25):4218-38. PubMed ID: 22680633
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in histone deacetylase targeted cancer therapy.
Hoshino I; Matsubara H
Surg Today; 2010 Sep; 40(9):809-15. PubMed ID: 20740342
[TBL] [Abstract][Full Text] [Related]
15. Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.
Wang B; Chen X; Gao J; Su L; Zhang L; Xu H; Luan Y
Bioorg Med Chem Lett; 2019 Sep; 29(18):2638-2645. PubMed ID: 31400938
[TBL] [Abstract][Full Text] [Related]
16. The Development of HDAC and Tubulin Dual-Targeting Inhibitors for Cancer Therapy.
Nie J; Wu H; Luan Y; Wu J
Mini Rev Med Chem; 2024; 24(5):480-490. PubMed ID: 37461341
[TBL] [Abstract][Full Text] [Related]
17. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of histone deacetylase as antitumor agents: A critical review.
Manal M; Chandrasekar MJ; Gomathi Priya J; Nanjan MJ
Bioorg Chem; 2016 Aug; 67():18-42. PubMed ID: 27239721
[TBL] [Abstract][Full Text] [Related]
19. Selective Histone Deacetylase Inhibitors with Anticancer Activity.
Ma N; Luo Y; Wang Y; Liao C; Ye WC; Jiang S
Curr Top Med Chem; 2016; 16(4):415-26. PubMed ID: 26268343
[TBL] [Abstract][Full Text] [Related]
20. Anticancer properties of chimeric HDAC and kinase inhibitors.
Biersack B; Polat S; Höpfner M
Semin Cancer Biol; 2022 Aug; 83():472-486. PubMed ID: 33189849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
